コンテンツへスキップ
Merck
  • Calnexin silencing in mouse neonatal cardiomyocytes induces Ca2+ cycling defects, ER stress, and apoptosis.

Calnexin silencing in mouse neonatal cardiomyocytes induces Ca2+ cycling defects, ER stress, and apoptosis.

Journal of cellular physiology (2013-09-17)
Nicolas Bousette, Cynthia Abbasi, Roxana Chis, Anthony O Gramolini
要旨

Calnexin (CNX) is an endoplasmic reticulum (ER) quality control chaperone that has been implicated in ER stress. ER stress is a prominent pathological feature of various pathologic conditions, including cardiovascular diseases. However, the role of CNX and ER stress has not been studied in the heart. In the present study, we aimed to characterize the role of CNX in cardiomyocyte physiology with respect to ER stress, apoptosis, and cardiomyocyte Ca(2+) cycling. We demonstrated significantly decreased CNX mRNA and protein levels by LentiVector mediated transduction of targeting shRNAs. CNX silenced cardiomyocytes exhibited ER stress as evidenced by increased GRP78 and ATF6 protein levels, increased levels of spliced XBP1 mRNA, ASK-1, ERO1a, and CHOP mRNA levels. CNX silencing also led to significant activation of caspases-3 and -9. This activation of caspases was associated with hallmark morphological features of apoptosis including loss of sarcomeric organization and nuclear integrity. Ca(2+) imaging in live cells showed that CNX silencing resulted in Ca(2+) transients with significantly larger amplitudes but decreased frequency and Ca(2+) uptake rates in the basal state. Interestingly, 5 mM caffeine stimulated Ca(2+) transients were similar between control and CNX silenced cardiomyocytes. Finally, we demonstrated that CNX silencing induced the expression of the L-type voltage dependent calcium channel (CAV1.2) but reduced the expression of the sarcoplasmic reticulum ATPase (SERCA2a). In conclusion, this is the first study to demonstrate CNX has a specific role in cardiomyocyte viability and Ca(2+) cycling through its effects on ER stress, apoptosis and Ca(2+) channel expression.

材料
製品番号
ブランド
製品内容

Supelco
カフェイン, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
カフェイン, powder, ReagentPlus®
Sigma-Aldrich
カフェイン, anhydrous, 99%, FCC, FG
Supelco
カフェイン, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
カフェイン 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
カフェイン, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
カフェイン, Sigma Reference Standard, vial of 250 mg
Supelco
融点スタンダード235~237°C, analytical standard
Sigma-Aldrich
カフェイン, anhydrous, tested according to Ph. Eur.
Supelco
Mettler-Toledo®キャリブレーション用物質ME 18872、カフェイン, traceable to primary standards (LGC)
Supelco
カフェイン 溶液, analytical standard, 1.0 mg/mL in methanol
Sigma-Aldrich
カフェイン, meets USP testing specifications, anhydrous
Sigma-Aldrich
カフェイン, BioXtra
Sigma-Aldrich
カフェイン, SAJ special grade, ≥98.5%
カフェイン, European Pharmacopoeia (EP) Reference Standard
システム適合性用カフェイン, European Pharmacopoeia (EP) Reference Standard